GSK (GSK) to Release Earnings on Wednesday

GSK (NYSE:GSKGet Rating) will be posting its quarterly earnings results before the market opens on Wednesday, February 1st. Analysts expect GSK to post earnings of $0.59 per share for the quarter. GSK has set its FY 2022 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

GSK (NYSE:GSKGet Rating) last released its quarterly earnings results on Wednesday, November 2nd. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.19. The firm had revenue of $9.22 billion for the quarter, compared to the consensus estimate of $7.75 billion. GSK had a return on equity of 32.18% and a net margin of 37.88%. On average, analysts expect GSK to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

GSK Stock Down 1.9 %

GSK stock opened at $34.70 on Wednesday. The company has a debt-to-equity ratio of 2.22, a current ratio of 0.97 and a quick ratio of 0.74. The stock has a market capitalization of $71.03 billion, a P/E ratio of 4.25, a P/E/G ratio of 1.19 and a beta of 0.66. GSK has a fifty-two week low of $28.47 and a fifty-two week high of $46.97. The business has a 50-day moving average of $34.97 and a 200-day moving average of $34.54.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 12th. Shareholders of record on Friday, November 18th were paid a $0.3695 dividend. This represents a $1.48 annualized dividend and a yield of 4.26%. The ex-dividend date of this dividend was Thursday, November 17th. GSK’s payout ratio is 16.05%.

Analyst Ratings Changes

A number of analysts have recently issued reports on GSK shares. Oddo Bhf upgraded shares of GSK from a “neutral” rating to an “outperform” rating in a report on Thursday, September 29th. AlphaValue upgraded shares of GSK to a “buy” rating in a research note on Thursday, December 8th. UBS Group downgraded GSK from a “neutral” rating to a “sell” rating in a research report on Friday, November 11th. TheStreet raised GSK from a “c+” rating to a “b-” rating in a research report on Friday, December 30th. Finally, Bank of America lowered GSK from a “neutral” rating to an “underperform” rating in a research report on Monday, December 5th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $1,583.57.

Hedge Funds Weigh In On GSK

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CreativeOne Wealth LLC acquired a new stake in GSK during the third quarter worth approximately $239,000. Kingsview Wealth Management LLC lifted its holdings in GSK by 2.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 17,926 shares of the pharmaceutical company’s stock worth $528,000 after purchasing an additional 384 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in GSK in the 3rd quarter valued at $1,155,000. Credit Suisse AG grew its holdings in GSK by 23.5% in the 3rd quarter. Credit Suisse AG now owns 9,574 shares of the pharmaceutical company’s stock valued at $282,000 after buying an additional 1,824 shares in the last quarter. Finally, Ironwood Wealth Management LLC. acquired a new stake in shares of GSK during the third quarter worth $271,000. 13.15% of the stock is owned by institutional investors.

GSK Company Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.

See Also

Earnings History for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.